The FREEDOM Trial: Denosumab Reduces Vertebral Fractures by 68% in Postmenopausal Women

Published in the New England Journal of Medicine in 2009, the FREEDOM trial (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months) was the pivotal phase 3 study that established denosumab as a major treatment option for postmenopausal osteoporosis. The trial enrolled 7,868 women aged 60 to 90 with T-scores between -2.5 and -4.0 at the lumbar spine or total hip, and randomized them to receive either 60 mg of denosumab or placebo via subcutaneous injection every six months for 36 months.

The results were compelling. Denosumab reduced the risk of new vertebral fractures by 68% compared to placebo (2.3% vs. 7.2%), hip fractures by 40% (0.7% vs. 1.2%), and nonvertebral fractures by 20% (6.5% vs. 8.0%). Bone mineral density increased by 9.2% at the lumbar spine and 6.0% at the total hip — gains that continued to accumulate in the 10-year extension study without evidence of plateauing. As a biologic RANKL inhibitor, denosumab represented a fundamentally different mechanism of action from bisphosphonates, giving clinicians a second major class of anti-resorptive therapy.

Why This Matters for Midlife Health

The FREEDOM trial expanded the treatment toolkit at a time when many patients were poorly served by existing options. Some women cannot tolerate oral bisphosphonates due to gastrointestinal side effects. Others have renal impairment that limits their use. Denosumab, given as a twice-yearly injection in a clinical setting, removes the daily pill burden and adherence challenges that undermine bisphosphonate effectiveness. For women diagnosed with osteoporosis during or after menopause, knowing that multiple evidence-based treatment options exist — and understanding how they differ — is essential for informed decision-making with their provider.

The Tracking Connection

Treatment with denosumab requires consistent follow-through — injections every six months without interruption, since discontinuation is associated with rapid bone loss and rebound vertebral fractures. Kairos™ helps users track injection schedules, log follow-up DXA scans, and monitor whether their treatment is producing the expected response over time. When the clinical literature shows that 10 years of continuous denosumab produces ongoing BMD gains, having a long-term record of your own treatment response is both motivating and clinically valuable.